Amgen’s (AMGN) Positive Rating Reiterated at Cann

Cann reiterated their positive rating on shares of Amgen, Inc. (NASDAQ:AMGN) in a research report report published on Wednesday morning. They currently have a $189.00 target price on the medical research company’s stock.

A number of other brokerages have also commented on AMGN. Mizuho set a $195.00 price target on Amgen and gave the company a buy rating in a research note on Friday, March 10th. Vetr lowered Amgen from a hold rating to a sell rating and set a $174.10 price target for the company. in a research note on Monday, March 13th. Oppenheimer Holdings Inc. reissued an outperform rating and set a $189.00 price target on shares of Amgen in a research note on Tuesday, March 14th. Piper Jaffray Companies reissued an overweight rating and set a $193.00 price target on shares of Amgen in a research note on Tuesday, March 14th. Finally, BMO Capital Markets reissued an outperform rating and set a $212.00 price target on shares of Amgen in a research note on Monday, March 6th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $187.41.

Amgen (NASDAQ:AMGN) opened at 168.61 on Wednesday. Amgen has a 1-year low of $133.64 and a 1-year high of $184.21. The stock has a market capitalization of $124.17 billion, a PE ratio of 16.47 and a beta of 1.15. The stock’s 50 day moving average price is $171.88 and its 200 day moving average price is $159.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, February 2nd. The medical research company reported $2.89 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.10. Amgen had a return on equity of 29.42% and a net margin of 33.59%. The company earned $5.97 billion during the quarter, compared to analyst estimates of $5.75 billion. During the same period in the prior year, the company earned $2.61 earnings per share. The firm’s revenue was up 7.7% on a year-over-year basis. On average, equities research analysts predict that Amgen will post $12.31 earnings per share for the current fiscal year.

Your IP Address:

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 8th. Stockholders of record on Wednesday, May 17th will be issued a $1.15 dividend. The ex-dividend date of this dividend is Monday, May 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.73%. Amgen’s payout ratio is 44.92%.

Several large investors have recently modified their holdings of the company. Thomas J. Herzfeld Advisors Inc. purchased a new position in Amgen during the fourth quarter valued at approximately $102,000. New York Life Trust Co. increased its position in Amgen by 54.8% in the third quarter. New York Life Trust Co. now owns 624 shares of the medical research company’s stock valued at $104,000 after buying an additional 221 shares during the last quarter. Penserra Capital Management LLC increased its position in Amgen by 100.0% in the third quarter. Penserra Capital Management LLC now owns 684 shares of the medical research company’s stock valued at $114,000 after buying an additional 342 shares during the last quarter. Oakworth Capital Inc. increased its position in Amgen by 1.4% in the third quarter. Oakworth Capital Inc. now owns 711 shares of the medical research company’s stock valued at $119,000 after buying an additional 10 shares during the last quarter. Finally, Nelson Roberts Investment Advisors LLC purchased a new position in Amgen during the third quarter valued at approximately $123,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/amgens-amgn-positive-rating-reiterated-at-cann/1708590.html

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *